Thank you for joining the weekly webinar!
We are admitting audience members from the waiting room.
Please allow a few moments for the webinar to begin.
The HEALEY ALS Platform Trial

➢ A Multistakeholder Partnership to Accelerate ALS Drug Development

Design and Launch

Platform Level Learnings

Regimen A-D Results

What’s Next
Platform trials have several advantages over traditional trials

Accelerating innovation for a cure

Merit Cudkowicz, MD, MSc
Sean M. Healey

“I lost the privilege of working on the human time clock on January 6, 2018
The ALS clock is a lot faster”

Sandy – Person with ALS
Platform trials may possibly be the best thing I have seen since diagnosis!" 

5-stars Patient-Centric Trial Design (PaCTD) Rating

“I have not seen this level of patient interest since the 90’s” 
(Darah Heitzman; Texas Neurology site PI)
The HEALEY ALS Platform Trial is grounded in robust academia – industry partnerships.
Common Protocol and Shared Infrastructure Allow for Operational and Scientific Efficiencies

- 1 Protocol
- (Phase 2/3)
- 1 single IRB
- Central Governance
- 7 Regimens
- 70+ Enrolling Sites
- ~1300 Participants

Regimen: Active Study Drug + Matching Placebo
Enroll in HEALEY ALS Platform Trial

Participant Flow

- Regimen A
- Regimen B
- Regimen C
- Regimen D

Active
Placebo
Active
Placebo
Active
Placebo
Active
Shared Placebo

Randomization

Shared infrastructure and common protocol allow sharing of placebo data

KEY ELIGIBILITY CRITERIA

1. Sporadic or familial ALS
   ➢ (possible, probable, lab-supported probable, or definite by revised EEC)
2. Time since weakness onset ≤ 3 years
3. Slow vital capacity ≥ 50% of predicted
4. Able to swallow
5. Either not take or be on stable dose of riluzole for ≥ 30 days
6. Either not take or have completed at least one cycle of edaravone
7. Either not take or have started Relyvrio/Albrioza ≥ 30 days prior to screening
The objective of each regimen is to provide a go / no go decision to inform the clinical development program of the regimen study drug.

**Primary Endpoint (Placebo-Controlled Period)**
Change from baseline through week 24 in disease severity as measured by the ALSFRS-R total score and survival

**Safety, Secondary, and Exploratory Endpoints**
(respiratory function, muscle strength, survival, biomarkers + regimen-specific endpoints)
The objective of each regimen is to provide a go / no go decision to inform the clinical development program of the regimen study drug.

- Interim analyses are planned to occur every 12 weeks and occur simultaneously for all actively enrolling regimens.
- Futility assessments for a regimen begin at the next interim analysis after the regimen had 40 randomized participants with the opportunity to complete at least 24 weeks of follow-up.
Patients are eager to learn about and participate in innovative research.

**Patient Navigator Team**
Building Community & Partnership in ALS Research

**Patient Navigator: Central Resource**
- 2,602 Total emails/phone calls/zoom calls with ALS families
- 630 Uses of Online Eligibility Checking Tool
- 39 Countries in contact about research

**Weekly Webinars: News & Updates**
- 115 Public Q&A webinars hosted to date
- 50+ Guest speakers featured
- 8,317 Total attendees, 71 Weekly average
- 40,553 Total views on YouTube

**Drug Science Q&A Webinars**
- 6 Webinars hosted (Regimens A-F)
- 8,481 Total views on YouTube
- 242 Questions answered live

(Data Collected Oct 2020-Mar 2023)
Providing research access across a diverse network of 70+ NEALS sites
The platform trial is a unique opportunity to move ALS biomarkers and new outcome measures forward

**DNA** – whole genome sequencing

**Neurofilaments** – for all regimens + regimen-specific biomarkers based on MOA

**Home Spirometry** – critical during the pandemic

**Speech Analysis** – emerging digital biomarker

Additional biomarkers/outcome measures considered for upcoming and future regimens (e.g., new patient-reported outcomes - **ROADS**; PBMCs for stem cell generation)
Home spirometry correlated with in-clinic spirometry

- Home Forced Vital Capacity (FVC) performed by participants with trained examiner on videoconference
- Home recordings reviewed centrally
- Clinic Slow Vital Capacity (SVC) performed by trained examiners
- Estimates of vital capacity are very similar by either method

Data include all participants with both in-clinic and home VC
The HEALEY ALS Platform Trial is a perpetual trial to provide decisive answers and direction with efficient execution.
Platform trials are becoming popular in the Neurosciences due to operational and scientific advantages over traditional trials:

(faster, more efficient use of resources, embedded natural history study, biomarker/endpoint development engine)

The HEALEY ALS Platform Trial is an adaptive, perpetual phase 2/3 trial – the trial launched in 2020, has included 70+ enrolling sites, 7 investigational drugs, and hundreds of participants so far. Additional regimens are ongoing, in start-up, or in the planning stages.

Initial learnings from the trial included go/no go decisions for the first 4 regimens, thus meeting the primary goal of the trial.

We continue to learn about novel biomarkers and endpoints collected in the trial, and plan to share data and samples with the scientific community as they become available.
Sharing our experience

Meetings with disease-specific networks both in the US and globally

Disease Areas
1. ALS
2. Alzheimer Disease
3. Duchenne Muscular Dystrophy
4. FSHD
5. Myotonic Dystrophy
6. Frontotemporal Dementia
7. Parkinson Disease
8. Progressive Supranuclear Palsy (PSP)
9. Traumatic Brain Injury
10. Spinal Cord Injury
11. Vanishing White Matter Disease
12. Depression
13. Neurofibromatosis (NF)
14. Scleroderma
15. Idiopathic Pulmonary Fibrosis
16. Fibrodysplasia Ossificans Progressiva (FOP)
17. Vascular Malformations

Master Protocol, Publications, and Other Documents Available at:
https://www.massgeneral.org/neurology/als/research/research-partners

E-mail:
Merit Cudkowicz:
mcedkowicz@mgh.harvard.edu
Sabrina Paganoni:
spaganoni@mgh.harvard.edu

New Regimen Application Form:
This trial is dedicated to all people living with ALS, their families, and friends.

We are immensely grateful to the NEALS sites, researchers, funders, foundations, industry partners, and all stakeholders who provided and continue to provide thoughtful feedback and invaluable support.

Your partnership in research is what keeps us filled with passion, dedication, and the commitment to develop new treatments for ALS.
HEALEY ALS Platform Trial Updates

MAY 31, 2023
4PM PT / 7PM ET

Register Here: https://bit.ly/3OyjUlG

4:00PM PT / 7:00PM ET

Wed, May 31 | Zoom call
Patient Navigation
Central resource for people living with ALS

Phone: 833-425-8257 (HALT ALS)
E-mail: healeyalsplatform@mgh.harvard.edu

Weekly webinar registration: [QR Code]
ALS Link sign-up: [QR Code]

Upcoming Webinars:
June 1st- Weekly Q&A and discussion of “what’s next” for the Platform Trial
June 8th- Weekly Q&A
June 15th- Weekly Q&A

Catherine Small
Allison Bulat